DOP2011000153A - Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para el uso en el trata miento del cancer - Google Patents

Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para el uso en el trata miento del cancer

Info

Publication number
DOP2011000153A
DOP2011000153A DO2011000153A DO2011000153A DOP2011000153A DO P2011000153 A DOP2011000153 A DO P2011000153A DO 2011000153 A DO2011000153 A DO 2011000153A DO 2011000153 A DO2011000153 A DO 2011000153A DO P2011000153 A DOP2011000153 A DO P2011000153A
Authority
DO
Dominican Republic
Prior art keywords
tieno
piridine
derivatives
kinase inhibitors
cancer treatment
Prior art date
Application number
DO2011000153A
Other languages
English (en)
Inventor
Michael R Michaelides
Michael L Curtin
Robin R Frey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of DOP2011000153A publication Critical patent/DOP2011000153A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms

Abstract

Compuestos que inhiben proteína quinasas, tales como aurora-quinasas y las familias de quinasas VEGFR y PDGFR, con un perfil de seguridad mejorado debido a una baja inhibición de CYP3A4, composiciones que contienen los compuestos y métodos de tratamiento de enfermedades usando los compuestos.
DO2011000153A 2008-12-05 2011-05-24 Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para el uso en el trata miento del cancer DOP2011000153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12028108P 2008-12-05 2008-12-05
US22376009P 2009-07-08 2009-07-08

Publications (1)

Publication Number Publication Date
DOP2011000153A true DOP2011000153A (es) 2011-06-30

Family

ID=41559043

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000153A DOP2011000153A (es) 2008-12-05 2011-05-24 Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para el uso en el trata miento del cancer

Country Status (26)

Country Link
US (2) US20100144783A1 (es)
EP (1) EP2373662B1 (es)
JP (1) JP5588458B2 (es)
KR (1) KR101639642B1 (es)
CN (1) CN102239171B (es)
AR (1) AR074481A1 (es)
AU (1) AU2009322270B2 (es)
BR (1) BRPI0921392A2 (es)
CA (1) CA2743592A1 (es)
CL (1) CL2011001312A1 (es)
CO (1) CO6382131A2 (es)
DO (1) DOP2011000153A (es)
EC (1) ECSP11011172A (es)
ES (1) ES2524966T3 (es)
HK (1) HK1159628A1 (es)
IL (1) IL212716A (es)
MX (1) MX2011005943A (es)
MY (1) MY179042A (es)
NZ (1) NZ592714A (es)
PA (1) PA8852401A1 (es)
PE (1) PE20110830A1 (es)
RU (2) RU2480472C2 (es)
TW (2) TWI441827B (es)
UA (1) UA103351C2 (es)
UY (1) UY32291A (es)
WO (1) WO2010065825A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
TWI441827B (zh) * 2008-12-05 2014-06-21 Abbvie Bahamas Ltd 具改良cyp安全性之激酶抑制劑
ES2559212T3 (es) * 2010-06-09 2016-02-11 Abbvie Bahamas Ltd. Formas cristalinas de inhibidores de cinasas
US8557995B2 (en) * 2010-06-09 2013-10-15 Abbvie Inc. Solid dispersions containing kinase inhibitors
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
US8911725B2 (en) 2010-06-23 2014-12-16 University Of Central Florida Research Foundation, Inc. Co-targeting of aurora A kinase and LIM kinase 1 for cancer therapy
US8436179B2 (en) 2011-07-20 2013-05-07 Abbvie Inc. Kinase inhibitor with improved solubility profile
TW201330850A (zh) 2011-12-14 2013-08-01 Abbvie Inc 包含激酶抑制劑之組合物
CA2882270A1 (en) * 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
US9238644B2 (en) * 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2015157360A1 (en) 2014-04-08 2015-10-15 Abbvie Inc. Processes to make protein kinase inhibitors
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
EP3983084A1 (en) * 2019-06-12 2022-04-20 Vanderbilt University Amino acid transport inhibitors and the uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188529A (en) 1966-06-09 1970-04-15 Wellcome Found Pyramidine Derivatives
US4357535A (en) 1980-04-30 1982-11-02 North American Philips Corporation Apparatus for inspecting hand-held articles and persons carrying same
GB8307154D0 (en) 1983-03-15 1983-04-20 Mk Electric Ltd Terminals
US4767766A (en) 1987-01-30 1988-08-30 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0436810Y2 (es) 1987-12-29 1992-08-31
US4843949A (en) 1988-08-29 1989-07-04 Pneumo Abex Corporation Fluid control valve with variable pressure gain
GB8912498D0 (en) 1989-05-31 1989-07-19 De Beers Ind Diamond Diamond growth
EP0438261A3 (en) 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0630031B1 (en) 1993-06-16 2002-08-14 E.I. Du Pont De Nemours And Company Water cleanable thick film paste composition
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
DE29511756U1 (de) 1995-07-20 1995-09-28 Ferco Int Usine Ferrures Flügelseitiges Ecklagerbeschlagteil für Drehkippfenster
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE19620508A1 (de) 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DK0977741T3 (da) 1997-04-22 2003-12-01 Neurosearch As Substituerede phenylderivater, deres fremstilling og anvendelse
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
CA2320730A1 (en) * 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
ATE464740T1 (de) 2000-12-15 2010-04-15 British Telecomm Übertagung von ton- und/oder bildmaterial
MXPA03007779A (es) 2001-03-14 2004-11-12 Lilly Co Eli Moduladores de los receptores de retinoides x.
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
US20050019424A1 (en) 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2004064778A2 (en) 2003-01-17 2004-08-05 Merck & Co. Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10303311A1 (de) 2003-01-28 2004-07-29 Basf Ag Addukte auf Basis cyclischer Verbindungen und ihre Verwendung als Gerbstoffe und Konservierungsmittel
EP1620094A4 (en) 2003-05-06 2010-04-28 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1809380A2 (en) 2004-11-11 2007-07-25 Achillion Pharmaceuticals, Inc. Inhibitors of hiv-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
US7566721B2 (en) 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
EP1951728A4 (en) 2005-11-04 2011-04-20 Glaxosmithkline Llc THIENOPYRIDINES AS INHIBITORS OF B-RAF KINASE
US20070135387A1 (en) * 2005-12-08 2007-06-14 Michaelides Michael R Inhibitors of protein kinases
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
TWI441827B (zh) * 2008-12-05 2014-06-21 Abbvie Bahamas Ltd 具改良cyp安全性之激酶抑制劑

Also Published As

Publication number Publication date
TW201026706A (en) 2010-07-16
RU2011127451A (ru) 2013-01-10
UA103351C2 (uk) 2013-10-10
AR074481A1 (es) 2011-01-19
WO2010065825A2 (en) 2010-06-10
RU2012156958A (ru) 2014-06-27
HK1159628A1 (en) 2012-08-03
JP5588458B2 (ja) 2014-09-10
PE20110830A1 (es) 2011-12-14
PA8852401A1 (es) 2010-07-27
AU2009322270A1 (en) 2011-07-14
KR20110091577A (ko) 2011-08-11
MX2011005943A (es) 2011-06-27
RU2480472C2 (ru) 2013-04-27
TWI441827B (zh) 2014-06-21
AU2009322270B2 (en) 2014-12-18
ECSP11011172A (es) 2011-08-31
IL212716A0 (en) 2011-07-31
EP2373662A2 (en) 2011-10-12
US20100144783A1 (en) 2010-06-10
MY179042A (en) 2020-10-26
CO6382131A2 (es) 2012-02-15
WO2010065825A3 (en) 2010-08-26
UY32291A (es) 2010-07-30
JP2012511016A (ja) 2012-05-17
CA2743592A1 (en) 2010-06-10
TW201431862A (zh) 2014-08-16
US8722890B2 (en) 2014-05-13
NZ592714A (en) 2013-03-28
CN102239171B (zh) 2014-06-11
KR101639642B1 (ko) 2016-07-14
IL212716A (en) 2013-10-31
TWI500621B (zh) 2015-09-21
US20120309783A1 (en) 2012-12-06
EP2373662B1 (en) 2014-09-24
CL2011001312A1 (es) 2011-10-07
CN102239171A (zh) 2011-11-09
ES2524966T3 (es) 2014-12-16
BRPI0921392A2 (pt) 2016-04-26

Similar Documents

Publication Publication Date Title
ECSP11011172A (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer.
SV2011003853A (es) Compuestos organicos
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CR20140544A (es) Compuestos para inhibir la progresión mitotica
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
NI201000219A (es) Derivados de pirimidina como inhibidores de cinasa.
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000156A (es) Compuestos heterocíclicos novedosos y usos de los mismos.
CO6440551A2 (es) Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa
DOP2011000171A (es) Compuestos organico
ECSP109953A (es) Derivados de piridazinona
NI201100048A (es) Aminotriazolopiridinas y su uso como inhibidores de la cinasa.
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
PE20211094A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
NI201500054A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CO6491087A2 (es) Compuestos de urea que contienen heteroarilo 5,6 bicíclicos como inhibidores de quinasa